Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

NCT00310804 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)
BIOLOGICAL: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)
BIOLOGICAL: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
BIOLOGICAL: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)

Sponsor

Novartis Vaccines